Comparison

Pemvidutide vs. Semaglutid

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Pemvidutide

The GLP-1 component suppresses appetite while the glucagon component raises energy expenditure and acts directly on hepatic fat metabolism — the combination is intended to mimic the complementary effects of diet and exercise.

Semaglutid

Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.

Evidence base

Highest evidence

Human trial

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Pemvidutide	Semaglutid
Switzerland	—	Prescription
Germany	Unapproved	Prescription
United States	Unapproved	Prescription

Full entries

Frequently asked questions

What is the difference between Pemvidutide and Semaglutid?: Pemvidutide is classified as "Metabolic", while Semaglutid is classified as "Metabolic". Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Pemvidutide or Semaglutid?: The highest available evidence level is "Human trial" for Pemvidutide and "Human RCT" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Pemvidutide and Semaglutid in Germany and the United States?: Germany: Pemvidutide — Unapproved, Semaglutid — Prescription. United States: Pemvidutide — Unapproved, Semaglutid — Prescription. These are factual summaries with source and review date on the individual pages.

Country

Pemvidutide

Semaglutid

Switzerland

—

Prescription

Germany

Unapproved

Prescription

United States

Unapproved

Prescription

Frequently asked questions

What is the difference between Pemvidutide and Semaglutid?

Pemvidutide is classified as "Metabolic", while Semaglutid is classified as "Metabolic". Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Pemvidutide or Semaglutid?

The highest available evidence level is "Human trial" for Pemvidutide and "Human RCT" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Pemvidutide and Semaglutid in Germany and the United States?

Germany: Pemvidutide — Unapproved, Semaglutid — Prescription. United States: Pemvidutide — Unapproved, Semaglutid — Prescription. These are factual summaries with source and review date on the individual pages.